NCT02551497已完成1 期
Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Cmax of CNV1014802 and a drug
研究概览
简要总结
This is a double-blind, randomised, placebo-controlled 3 period study to evaluate the interaction between a drug and CNV1014802 in healthy male and female subjects. It is planned to enrol 36 subjects.
详细描述
This study was previously posted by Convergence Pharmaceuticals, Ltd., which has been acquired by Biogen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males, or non-pregnant, non-lactating healthy females either of non-child bearing potential, or taking an approved method of contraception for the duration of the study
- •Age 18 to 55 years of age, inclusive
- •Non-smoking subjects with body weight ≥45 kg
- •Body mass index (BMI) of 18 to 32 kg/m2 (inclusive)
- •Must be willing and able to communicate and participate in the whole study
- •Must provide written informed consent
- •Must agree to use an adequate method of contraception
排除标准
- •Participation in a clinical research study within the previous 3 months
- •Subjects who are study site employees, or immediate family members of a study site or sponsor employee
- •Subjects who have previously been enrolled in this study
- •History of any drug or alcohol abuse in the past 2 years
- •History of regular alcohol consumption within 6 months of the study (male subjects >21 units per week or female subjects >14 units per week; 1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
- •Positive alcohol breath test
- •Current smokers and those who have smoked within the last 6 months. A breath carbon monoxide reading of greater than 10 ppm at screening
- •Females of childbearing potential who are pregnant or lactating (female subjects must have a negative urine pregnancy test at admission)
- •Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
- •Clinically significant abnormal biochemistry, haematology or urinalysis
- •Positive drugs of abuse test result
- •Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
- •Positive genotyping test
- •History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the investigator
- •Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
- •Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period
- •Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than hormone replacement therapy [HRT]/hormonal contraception not containing ethinyl estradiol) or herbal remedies in the 14 days before IMP administration
- •Significant medical history of fainting or vasovagal attacks
- •History of uncontrolled or poorly controlled hypertension
- •Semi-supine systolic BP <90 mmHg or >140 mmHg, or diastolic BP >100 mmHg after 3 assessments
- •QTcB or QTcF of >450 msec in male subjects or >470 msec in females
- •Presence or history of any clinically significant abnormality in vital signs or ECG
- •Presence of any medical condition, which in the opinion of the investigator may interfere with the study procedures or compromise subject safety
- •Medical history of clinically significant depression
- •History of suicide attempt within 6 months prior to screening
- •History of acute porphyria
- •History of cardiac conduction disorders with the exception of 1st degree heart block
- •Mentally or legally incapacitated
- •Unwillingness or inability to follow the procedures outlined in the protocol, or to comply with study restrictions on smoking, concomitant medications and diet
- •Failure to satisfy the investigator of fitness to participate for any other reason
研究组 & 干预措施
Other drug
Experimental
Other drug BID
干预措施: CNV1014802 (Drug)
placebo
Experimental
Placebo to match BID
干预措施: CNV1014802 (Drug)
结局指标
主要结局
Cmax of CNV1014802 and a drug
时间窗: 5 days
number of AEs
时间窗: Days 16 to 21
ECG
时间窗: Days 16-21
safety laboratory tests
时间窗: Days 16-21
heart rate
时间窗: Days16-21
Blood pressure
时间窗: Days16-21
AUC(0-tau) of CNV1014802 and a drug
时间窗: days 1-28
次要结局
- CNV1014802 Tmax(days 1-28)
- CNV1014802 Ctrough(days 1-28)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia PatientsPrimary InsomniaNCT00397189Neurim Pharmaceuticals Ltd.930
进行中（未招募）
3 期
A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid ArthritisModerately to Severely Active Rheumatoid ArthritisNCT06738719Celltrion192
已完成
2 期
Efficacy of TPI ASM8 During a 14-Day Allergen ChallengeAsthmaNCT01158898Syntara16
已完成
3 期
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderMajor Depressive DisorderNCT06058013Neumora Therapeutics, Inc.430
已完成
4 期
A Double-blind Randomized, Placebo-controlled, Crossover Study of Single Doses of OROS Methylphenidate Hydrochloride (CONCERTA) and Long-acting Methylphenidate Hydrochloride (RITALIN LA) in Healthy AdultsHealthy VolunteersNCT00302354Massachusetts General Hospital50